Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18003902 | 0.81 | MGAM (0.55) | KMT2ASMN1; SMN2MEN1RAB9ANPC1 | |
| SCHEMBL10972611 | 0.81 | CA1 (0.50) | KMT2ASMN1; SMN2MEN1CSNK2A2CSNK2A1 | |
| SCHEMBL12882390 | 0.75 | SMN1; SMN2 (0.55) | KMT2ASMN1; SMN2MEN1CSNK2A2CSNK2A1 | |
| SCHEMBL3826842 | 0.72 | HDAC1 (0.44) | KMT2ASMN1; SMN2MEN1CSNK2A2CSNK2A1 | |
| SCHEMBL1143313 | 0.71 | KDM4E (0.66) | SMN1; SMN2CSNK2A2CSNK2A1RAB9ANPC1 | |
| SCHEMBL8044729 | 0.71 | SMN1; SMN2 (0.43) | KMT2ASMN1; SMN2MEN1CSNK2A2CSNK2A1 | |
| SCHEMBL21346519 | 0.71 | SMN1; SMN2 (0.60) | KMT2ASMN1; SMN2MEN1CSNK2A2CSNK2A1 | |
| SCHEMBL14970084 | 0.71 | NPC1 (0.50) | KMT2ASMN1; SMN2MEN1CSNK2A2CSNK2A1 | |
| SCHEMBL14814714 | 0.69 | ABL1 (0.42) | CSNK2A1RAB9ANPC1KDM4EHDAC1 | |
| SCHEMBL8840334 | 0.69 | CSNK2A2 (0.56) | KMT2ASMN1; SMN2MEN1CSNK2A2CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2760854-B1 | IMIDAZOLE DERIVATIVES AS CYP17 INHIBITORS FOR THE TREATMENT OF CANCER | ASANA BIOSCIENCES LLC (US) | 2017-08-30 | — | — | EP | disclosed |
| EP-2760854-B1 | IMIDAZOLE DERIVATIVES AS CYP17 INHIBITORS FOR THE TREATMENT OF CANCER | ASANA BIOSCIENCES LLC (US) | 2017-08-30 | — | — | EP | disclosed |
| US-20170073339-A1 | PYRIDINE DERIVATIVES | ENDO PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20170073339-A1 | PYRIDINE DERIVATIVES | ENDO PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20170073339-A1 | PYRIDINE DERIVATIVES | ENDO PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-9533981-B2 | Pyridine derivatives | ASANA BIOSCIENCES, LLC (US) | 2017-01-03 | — | — | US | disclosed |
| US-9533981-B2 | Pyridine derivatives | ASANA BIOSCIENCES, LLC (US) | 2017-01-03 | — | — | US | disclosed |
| US-20160340310-A9 | Pyridine Derivatives | ENDO PHARMACEUTICALS, INC. | 2016-11-24 | — | — | US | disclosed |
| US-20160340310-A9 | Pyridine Derivatives | ENDO PHARMACEUTICALS, INC. | 2016-11-24 | — | — | US | disclosed |
| US-20160340310-A9 | Pyridine Derivatives | ENDO PHARMACEUTICALS, INC. | 2016-11-24 | — | — | US | disclosed |
| US-20130085164-A1 | Imidazole Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085164-A1 | Imidazole Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085164-A1 | Imidazole Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085148-A1 | Pyridine Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | US | disclosed |
| WO-2013049559-A1 | PYRIDINE DERIVATIVES | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013049559-A1 | PYRIDINE DERIVATIVES | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | WO | disclosed |
| US-20130085148-A1 | Pyridine Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | US | disclosed |
| WO-2013049565-A1 | IMIDAZOLE DERIVATIVES AS CYP17 INHIBITORS FOR THE TREATMENT OF CANCER | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | WO | disclosed |
| US-20130085148-A1 | Pyridine Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | US | disclosed |
| EP-0557834-A1 | Process for the preparation of heterocyclic aldehyds and ketones | BASF Aktiengesellschaft (DE) | 1993-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085148-A1 | Pyridine Derivatives | CYP2A7, CYP21A2, CYP3A7 | KMT2A 2460/4885SMN1; SMN2 2677/4885MEN1 3533/4885 |
| US-20170073339-A1 | PYRIDINE DERIVATIVES | CYP21A2, CYP26A1, CYP11B1 | KMT2A 2239/4885SMN1; SMN2 1474/4885MEN1 3281/4885 |
| US-20160340310-A9 | Pyridine Derivatives | CYP2A7, CYP21A2, CYP3A7 | KMT2A 2460/4885SMN1; SMN2 2677/4885MEN1 3533/4885 |
| US-20130085164-A1 | Imidazole Derivatives | CYP17A1, CYP2A7, CYP11B1 | KMT2A 1810/4885SMN1; SMN2 2574/4885MEN1 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.